Carl Zeiss Meditec AG (ETR:AFX) has received a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is €65.00 ($75.58).
AFX has been the topic of a number of research reports. Kepler Capital Markets set a €62.00 ($72.09) target price on Carl Zeiss Meditec and gave the stock a “sell” rating in a research report on Monday, August 27th. Commerzbank set a €51.00 ($59.30) target price on Carl Zeiss Meditec and gave the stock a “neutral” rating in a research report on Wednesday, August 8th. Independent Research set a €73.00 ($84.88) price target on Carl Zeiss Meditec and gave the company a “neutral” rating in a research report on Monday, August 13th. Nord/LB set a €62.00 ($72.09) price target on Carl Zeiss Meditec and gave the company a “sell” rating in a research report on Tuesday, September 4th. Finally, HSBC set a €75.00 ($87.21) price target on Carl Zeiss Meditec and gave the company a “neutral” rating in a research report on Thursday, September 6th.
Shares of ETR:AFX traded down €1.00 ($1.16) during trading on Thursday, reaching €69.40 ($80.70). 157,114 shares of the stock were exchanged, compared to its average volume of 94,405. Carl Zeiss Meditec has a 1-year low of €37.53 ($43.64) and a 1-year high of €55.25 ($64.24).
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.